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Abstract 
Objectives: To investigate the effectiveness, safety and reasons for premature discontinuation of direct-
acting antivirals (DAAs) in a diverse population of HIV/HCV co-infected individuals in Europe. 
Methods: All HIV/HCV co-infected individuals in the EuroSIDA study that started interferon (IFN) 
free DAA treatment between 1/6/2014 and 1/3/2018 with ≥12 weeks of follow-up after treatment stop 
were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-
RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore 
factors associated with SVR12. 
Results: 1042 individuals started IFN-free DAA treament after 1/6/2014 and were included, 862 
(82.2%) had a known response to treatment, 789 (91.5%, 95% CI 89.7-93.4) of which achieved 
SVR12. There were no differences in SVR12 across regions of Europe (p=0.84). After adjustment, the 
odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir +/- RBV (aOR 
0.21 (95% CI 0.08-0.53) or ombitasvir/paritaprevir/dasabuvir +/- RBV (aOR 0.46 (95% CI 0.22–1.00) 
compared to sofosbuvir/ledipasvir +/- RBV. 43 (4.6%) individuals had one or more components of 
their HCV regimen stopped early, most commonly due to toxicity (n=14); of these 14, 11 were treated 
with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event 
(n=15.3%) and was related to treatment with atazanavir and ribavirin. 
Conclusions: Our findings from real-world data on HIV/HCV co-infected individuals across Europe 
show DAA treatment is well tolerated, and that high rates of SVR12 can be achieved in all regions of 
Europe. 
Keywords: HIV/HCV co-infection, DAA treatment, DAA safety, SVR, Europe   
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Introduction 
Globally, 38 million people were estimated to have human immunodeficiency virus (HIV) by the end 
of 2019 [1]. Among these, 2.3 million individuals were also co-infected with hepatitis C virus (HCV) 
[2] including more than 700.000 individuals in the World Health Organisation (WHO) European 
Region [2]. In the absence of antiretroviral therapy, HIV co-infection accelerates fibrosis progression 
particularly in those with low CD4 cell counts [3, 4]. HIV treatment guidelines now recommend 
starting antiretroviral therapy (ART) at HIV diagnosis for all patients, but it is also important to 
identify and treat HCV early to prevent the progression to liver disease and onward transmission to 
others [5, 6].  
With the advent of direct-acting antiviral (DAA) therapy against HCV, more than 95% of those 
included in phase 3 clinical trials achieve a sustained virological response (SVR) with similar high 
SVR rates reported in both HCV mono-infected [7-9] and HIV/HCV co-infected individuals [10-13]. 
An SVR is associated with a significant improvement in liver-related and all-cause mortality [14-16]. 
This revolution in HCV treatment prompted the WHO to adopt a list of targets to eliminate viral 
hepatitis as a public health threat by 2030. These targets include providing HCV treatment to 80% of 
eligible patients which will lead to cure in more than 90% of patients, and have a major impact on 
HCV-related mortality [17].  
Randomised controlled trials remain the gold standard for drug approval, however, participants are 
generally highly selected and differ from the general population that will be receiving the treatment 
post licencing. So far, real-world data from national or local HIV/HCV cohorts from Western Europe 
and the US have shown SVR rates only slightly lower than reported in clinical trials [18-22], but data 
from demographically diverse populations in Europe, in particular Central and Eastern Europe are still 
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missing. Our study aimed to investigate the effectiv ness and safety of DAAs in HIV/HCV co-infected 
individuals from the large pan-European EuroSIDA cohort study. 
 
Methods 
EuroSIDA study participants  
EuroSIDA (http://www.chip.dk/Ongoing-Studies/EuroSIDA/About) is a large ongoing prospective 
observational cohort study that began enrolling HIV-1 positive patients in 1994. There are currently 
data on over 22000 HIV-positive individuals aged 16 or older from 100 centres in 35 European 
countries, Israel and Argentina. Since 1994, ten patient cohorts have been recruited through enrolment 
waves at regular intervals. While individuals in cohort one to nine were enrolled irrespective of HCV 
status, HIV positive individuals in cohort ten were also required to be anti-HCV positive (regardless of 
HCV-RNA status). At recruitment, demographic and clini al data is collected as well as complete ART 
history, CD4 count, HIV-RNA, anti-HCV, HCV-RNA, HCV genotype and hepatitis B surface antigen. 
Data are then collected prospectively at clinical sites and sent to the EuroSIDA coordinating centre a 
12-monthly intervals (6 monthly until 2015). Where possible, participants continue to be followed if 
they transfer to another EuroSIDA clinic. Further dtails on the EuroSIDA cohort have been reported 
elsewhere [23], and can be found on the EuroSIDA websit  (https://www.chip.dk/Studies/EuroSIDA).  
 
This analysis included all individuals under follow-up in EuroSIDA that received interferon-free DAA 
therapy after 1 June 2014, as this is when EuroSIDA began collecting detailed information about HCV 
treatment including data on reasons for early discontinuation and treatment-limiting toxicities of HCV 
therapy. All reported HCV treatment toxicities were reviewed by a clinician. Baseline was defined as 
the start date of DAA treatment. Individuals that did not have at least 12 weeks of follow-up after 
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completing DAA treatment were not included in this analysis (unless they died within 12 weeks of 
stopping treatment). Baseline characteristics were d fined based on the most recent measurement prior 
to baseline. Fibrosis stage was defined using a consensus definition [24], and was based on the most 
recent fibrosis marker measured prior to the baseline. When more than one fibrosis marker was 
measured on the same day, then priority was given to a biopsy result, followed by transient 
elastography, AST to Platelet Ratio Index (APRI) score then finally a plasma hyaluronic acid result. 
Information on how fibrosis data is collected and defined in EuroSIDA has been specified elsewhere 
[25]. SVR12 was defined as undetectable HCV-RNA 12 weeks or later after stopping DAA treatment. 
Treatment failure was defined as detectable HCV-RNA at the first measurement at the end of treatment 
or later, or individuals that died before SVR could be determined. Analysis of laboratory adverse 
events (AEs) was carried out on individuals that strted treatment between 1 June 2014 and 1 October 
2016, as this is when data on laboratory values during therapy were systematically collected.  
Statistical analysis 
Baseline characteristics of individuals with a know treatment outcome were compared between those 
with and without SVR12, using the chi-squared test for categorical variables and the Kruskal-Wallis 
test for continuous variables. Reasons for stopping treatment early and AE were also described. 
Logistic regression was used to calculate the odds of having a known response to DAAs, and factors 
associated with achieving SVR12. Factors adjusted for were age, gender, region of Europe 
(South/Argentina, Central West, North, Central East, East; regions are defined in [23]), ethnicity, HIV 
risk group (MSM, IDU, other), CD4 nadir  and baselin  CD4 cell count (both as continuous variable 
(per 100/mm3) and categorised as ≤500 , >500 (cells/mm3), and unknown), baseline HIV-RNA ( ≤500 , 
>500 copies per mL, unknown), HCV treatment regimen, stage of liver fibrosis, HCV genotype, HCV-
RNA (positive and unquantified, <500,000, ≥500,000 IU/mL) ever received cART (defined as at lest 
three antiretroviral drugs from at least two drug classes) at baseline, prior HCV treatment, baseline dat
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(continuous (per 6 months later) and categorised as <2016 and ≥2016), treatment duration (continuous 
(per 1 week later) and categorised as  ≤12 and >12 weeks), HBsAg,  prior AIDS,  prior non-AIDS 
defining event (malignancy, cardiovascular disease , end-stage liver disease, end-stage renal disease, 
and pancreatitis). Variables found to be associated with the outcome in univariable analyses (p<0.1) 
were included in multivariable models. The Division f AIDS (DAIDS) grading table was used to 
determine the severity of AEs for different biomarkers (haemoglobin, leukocytes, neutrophils, platelet 
count, s-creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), and bilirubin), where grade 1 indicates a mild event, grade 2 indicates a moderate 
event, grade 3 indicates a severe event, and grade 4 indicates a potentially life-threatening event [26]. 
SAS 9.4 was used for all analysis (version 9.4; SAS Institute, Cary, North Carolina, USA). 
 
Results 
Study population and treatment regimens 
Among the 1234 individuals that started interferon-free DAA treatment between 1/6/2014 and 
1/3/2018, 1033 individuals had at least 12 weeks of FU after ending treatment, and 9 individuals died 
within 12 weeks of stopping treatment, therefore 1042 individuals were included in this analysis (figure 
1). Of the 1042 individuals, most received a DAA regimen consisting of sofosbuvir/ledipasvir +/- 
ribavirin (RBV) (n=501, 48.1%), 17.6% (n=183) received sofosbuvir/daclatasvir +/- RBV, 12.8% 
(n=133) received ombitasvir/paritaprevir/dasabuvir +/- RBV, 5.0% (n=52) received 
ombitasvir/paritaprevir +/- RBV, 4.7% (n=49) receivd sofosbuvir + RBV, and the remaining 11.9% 
(n=124) received other combinations of DAAs +/- RBV. Of the 1042 individuals included in this 
analysis, 379 (36.4%) had RBV included in their DAA regimen.  
 
AC
CE
PT
ED
Copyright  20 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 20
8 
 
Virological response to treatment 
Among the 1042 individuals included in this analysis, 789 (75.7%) individuals achieved SVR12; 73 
(7.0%) were treatment failures (this included 9 deaths within 12 weeks of stopping treatment); 89 
(8.5%) had a negative HCV-RNA result after stopping treatment but had no follow-up HCV-RNA 
result 12 weeks after stopping treatment; and 91 (8.9%) had an unknown treatment response. 
Therefore, 862/1042 (82.7%) individuals had a known response to their HCV treatment while 180/1042 
(17.3%) had an unknown response. In multivariable analysis we found that individuals with an 
unknown treatment outcome were similar to those with a known treatment outcome, however the odds 
of having a known response to treatment was lower among individuals that started treatment in 2016 or 
later [adjusted odds ratio (aOR)=0.62, 95% confidence i terval (CI) 0.43-0.88], and among those who 
had ‘other’ treatment regimens, and higher among indiv duals that received 
ombitasvir/paritaprevir/dasabuvir +/- RBV (compared to sofosbuvir/ledipasvir +/- RBV) [aOR=0.41, 
95% CI=0.26-0.65 and aOR=2.05, 95% CI=1.06-3.98], respectively. In the univariable analysis, 
individuals from East/Central Eastern Europe (compared to Southern Europe) had  a lower odds of 
having a known response to treatment (OR=0.5, 95% CI=0.31-0.79), however after adjusting for other 
variables the association was not as strong (aOR=0.63, 95% CI=0.38-1.04). Among the 862 individuals 
with a known response to treatment, 789 (91.5%, 95%CI 89.7-93.4) achieved SVR12 and 73 (8.5%) 
were treatment failures. 
Baseline characteristics  
Table 1 shows the baseline characteristics at time of starting HCV-treatment in the 862 individuals with 
a known SVR12 status. The majority were male (78.0%), of white ethnicity (89.3%), and had a median 
age of 51 years (interquartile range [IQR]: 45-55). The median CD4 count was 605 cells/mm3 (IQR: 
431-813), 94.9% of individuals had an HIV-RNA value ≤500 cp/ml and 96.9% had received cART. Of 
the 862 individuals with a known response, 772 (89.6%) had been genotyped. Genotype 1 was the most 
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common (64.2%), followed by genotype 4 (17.5%), genotype 3 (16.5%), and genotype 2 (1.8%). 817 
(94.8%) individuals had at least one liver fibrosis marker recorded one year prior to their treatment 
start, 23.1% of which had cirrhosis (METAVIR stage F4). The proportion of individuals that achieved 
SVR12 was significantly lower in individuals with cirrhosis (p=0.012), with a SVR12 rate of 93.2% in 
those with METAVIR F0-F3, and 86.4% in those with cirrhosis. For the five most commonly used 
DAA regimens, the SVR12 rate was >90% in all except sofosbuvir/simeprevir +/- RBV where only 
29/39 (74.4%) achieved SVR12. A total of 163 (18.9%) individuals had a previous non-AIDS defining 
illness (non-ADI). The most common non-ADI was end-stage liver disease (excluding hepatocellular 
carcinoma (HCC)) (n=58; of whom 32 [55.2%] also had cirrhosis), followed by cardiovascular disease 
(n=55), non-AIDS defining malignancy (excluding HCC) (n=46), pancreatitis (n=21), HCC (n=17), 
and end-stage renal disease (n=9). The proportion of individuals that achieved SVR12 was significantly 
lower among individuals that had a non-ADI compared to those that did not (86.5% vs 92.7%; 
p=0.0105). However, when ESLD was excluded from non-ADI, the difference was no longer 
significant (91.8% vs 90.0%, p=0.4962). The SVR rate in individuals with ESLD was 77.6%, 
compared to 92.5% in individuals without ESLD (p<0.0001). 
Predictors of treatment response 
The odds of achieving SVR12 was assessed in individuals with a known response to HCV-RNA 
treatment (n=862). After adjustment, factors found to decrease the odds of achieving SVR12 were 
having a non-ADI [aOR=0.53, 95% CI 0.0.30–0.95] and receiving sofosbuvir/simeprevir +/- RBV 
[aOR=0.21, 95% CI 0.08–0.53] or ombitasvir/paritaprevir/dasabuvir +/- RBV [aOR=0.21, 95% 
CI=0.08-0.53] compared to sofosbuvir/ledipasvir +/-RBV (Figure 2). While persons HCV-RNA 
positive but unknown level of viremia had lower rates of SVR12 (aOR 0.50, 95% CI 0.25–0.99), there 
were no differences between those with HCV-RNA levels quantified above or below 500,000 
copies/mL.  After excluding individuals with ESLD, the association between non-ADI and SVR12 was 
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no longer significant aOR=0.77, 95% CI 0.40-1.49. In contrast, ESLD was associated with lower 
SVR12 in both univariable and multivariable analysis [OR=0.28, 95% CI 0.14-0.55 and aOR=0.34 
95% CI 0.16-0.74, respectively. In univariate analysis, those with cirrhosis (compared to fibrosis ≤F3) 
had lower odds of achieving SVR [OR=0.47, 95% CI=0.28-0.71], but after adjustment, cirrhosis was 
no longer associated with SVR12 [aOR 0.61 (0.34-1.09)]. In post-hoc, analysis we explored a potential 
interaction between risk group and region, however this was not significant (p>0.1). Age group, sex, 
ethnicity, region of Europe, HIV risk group, CD4 count, CD4 nadir, HIV-RNA, AIDS event, treatment 
duration (≤12 weeks vs >12 weeks), HCV genotype, cART, prior HCV treatment, and HBV co-
infection were not included in the model as they either had p>0.1 in the univariable analysis (there was
no evidence of an association with SVR12), or there was insufficient data to explore the association.  
 
Reasons for stopping treatment early 
Of the 1042 individuals included in this analysis, 934 (89.6%) individuals had information on whether 
they stopped treatment earlier than scheduled. Of these, 43 (4.6%) individuals had one or more 
components of their HCV regimen stopped early. Not all individuals stopped their entire treatment 
regimen, as 14 individuals only stopped RBV early. Of the 43 individuals that stopped treatment early, 
24 (55.8%) achieved SVR12, 11 (25.6%) were treatmen failures (including 4 deaths within 12 weeks 
of stopping treatment), and 8 (18.6%) had an unknown treatment response. The most common reason 
for stopping treatment early was reported adverse events (AEs) (n=14, 12 of which were on RBV). 
Among the 14 who stopped treatment early due to AEs, 11 stopped only RBV and completed the 
remaining DAA treatment as planned.  9 of these 11 had known response to treatment, of whom 8 
(88.8%) achieved SVR12.  The most common AE was anaemia (n=8), followed by, rash (n=2), 
neuropathy (n=1), tiredness, dizziness, anorexia (n=1), intolerance, rash, fatigue, and abdominal pain 
(n=1), and nausea and vomiting (n=1). Other reasons for stopping treatment early were substance abuse 
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(n=4), physicians decision (n=4), patients decision (n=2), virological failure (n=2), drug interaction 
(n=2), drug out of stock (n=1), or lost to follow-up (n=1), with 13 individuals having other/unknown 
reasons for stopping early. Two individuals died during treatment with cause of death reported as 
hepatitis with cirrhosis and an unspecified malignancy which was not HCC.  An additional two 
individuals died within 12 weeks of stopping treatment, one due to HCC and the other with unknown 
cause of death. The median treatment time for those that stopped treatment early was 8 weeks (IQR 4-
12). Those who stopped treatment early due to AEs were treated for a median of 9 weeks (IQR 4-14), 
and those with non-AE reasons for stopping treatmen early were treated for a median of 8 weeks (IQR 
4-12). Individuals who did not have any reported trea ment interruption were treated for a median of 12 
weeks (IQR 12-15).  
 
Laboratory adverse events 
Table 2 shows the number of individuals with pre-trea ment laboratory AEs and during HCV treatment 
AE (graded 1 to 4) for different biomarkers. 555 individuals were eligible for this analysis as they 
started HCV treatment between 1/6/2014 and 1/10/2016. Of those eligible, 511 (92.1%) had laboratory 
data available during their treatment regimen and were included in this analysis.  
Of the 511 individuals included in this analysis, 363 (71.0%) had at least 1 AE, and overall 770 AEs 
were recorded among them. The majority of AEs during treatment were grade 1 or 2 (n=651, 84.5%). 
The highest proportion of AEs during treatment was for elevated alkaline phosphatase (54.6%), 
followed by bilirubin (43.7%), and platelet count (28.6%), with a small proportion of individuals with 
neutropenia (1.3%) and leukopenia (3.0%). The most c mmon grade 3 or 4 AEs during treatment was 
raised bilirubin levels (15.3%), followed by reduced platelet count (5.1%) and haemoglobin (1.6%), 
and increased alanine aminotransferase (ALT) (1.4%). Among those with a grade 3 or 4 ALT elevation, 
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one individual was HBsAg positive and received lamivud ne as the only HBV active treatment. We do 
not have information about the HBV-DNA levels during HCV treatment. Of the 119 grade 3 or 4 AEs 
that occurred during treatment, 57.1% occurred in individuals on RBV. Also, 56.7% of the 67 
individuals with a grade 3 or 4 bilirubin AE were on atazanavir and 65.7% received ribavirin. Among 
the individuals with grade 3 or 4 AEs, only two stopped their HCV treatment earlier than scheduled due 
to toxicity and none of them died during treatment. 
 
Discussion 
Results from this analysis including a large heterog nous population of HIV/HCV co-infected 
individuals across Europe receiving interferon-free DAA therapy in a real-world setting confirm the 
high SVR rates reported from other cohorts in Western Europe and the US [18-22]. Among participants 
where SVR12 could be determined, 91.5% achieved SVRwhich is only slightly less than reported in 
clinical trials [10-13].  
Almost 20% of the persons who started HCV treatment did not have data to ascertain whether 
they achieved SVR12, although a significant number of these have an end of treatment response.  
Possible reasons include that HCV RNA was measured and not reported to EuroSIDA, or that HCV 
RNA has not been measured locally.  The former is les likely given the rigorous quality assurance in 
place and that missing data has been requested by the coordinating team.  Individuals with cirrhosis 
were less likely to achieve SVR12 in unadjusted analysis. After adjusting for confounders, we still saw 
a trend towards lower odds of SVR12 in those with cirrhosis, but the association was no longer 
statistically significant.  We adjusted for previous non-ADI as a composite variable, but in a post-hoc 
analysis, those individuals with ESLD had lower odds of SVR12, which further indicates that cirrhosis 
influences the treatment outcomes negatively. The composite variable non-ADI includes any non-ADI 
prior to baseline, and among the 58 individuals that had ESLD, 25 also had another non-ADI. These 
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individuals may have more progressed disease and therefore it is possible that the association between 
ESLD and SVR12 may be partly attributable to confouding by indication. Findings from other large 
real-life cohort studies including the German Hepatitis C Cohort [22], a cohort of US veterans [20], and 
a co-infection registry in Madrid, Spain [19] all showed lower SVR12 rates among people with 
cirrhosis, whereas a French cohort study that included fewer individuals with cirrhosis (n=162) found 
no impact of cirrhosis on SVR12 [21]. We did not find any association between other HIV related 
factors (including HIV-RNA, CD4 cell count, use of ART or prior AIDS) again in agreement with 
other cohort studies [20-22]. In contrast, data from the Spanish co-infection registry that included 2,369 
patients, found higher odds of HCV treatment failure among those with a prior AIDS defining disease 
and those with a CD4 cell count less than 200 cells/mm3 which indicates that a subgroup of co-infected 
individuals with advanced HIV disease may have sub-optimal HCV treatment outcomes, but further 
studies are warranted to confirm these findings [19].  
 Our study is one the first to present data on patients from Central-East and Eastern Europe. The 
SVR rates were above 90% in all regions and there was no evidence of regional differences in 
SVR.Data from Central-East and Eastern Europe are still limited, and further investigation is 
warranted.  
Among the five most commonly used DAA regimens, only the combination of sofosbuvir and 
simeprevir showed SVR rates less than 90%. Compared with sofosbuvir/ledipasvir, participants on 
sofosbuvir/simeprevir and ombitasvir/paritaprevir/dasabuvir +/- RBV also had significantly lower odds 
of SVR after adjustment. Lower SVR rates for sofosbuvir/simeprevir are also in agreement with 
findings from the Madrid co-infection registry [19] whereas this and another large real-life study did 
not find lower SVR rates among those receiving ombitasvir/paritaprevir/dasabuvir [19, 20]. The 
combination of sofosbuvir and simeprevir is no longer recommended by European HCV treatment 
guidelines for HIV infected persons, whereas  ombitasvir/paritaprevir/dasabuvir is considered an 
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alternative treatment option [27].  There were no differences in the odds of SVR12 comparing those 
with high or low HCV RNA levels (based on a cut-off  500,000 copies/mL)  
 
The majority of individuals completed their HCV treatment as scheduled, with only 4.1% known to 
have stopped one or more drugs of the treatment regimen early. A third of all premature treatment stop 
were due to toxicity and in most cases (11 out of 14) ribavirin was the only drug in the regimen that 
was stopped due to well-known RBV adverse effects.  The majority went on to achieve SVR12 after 
stopping RBV.  Depending on DAA regimen, RBV is often added if cirrhosis is present, in which case 
the individual may be more at risk of an adverse evnt [27].  
 
Laboratory AEs were seen in 71% during treatment, with 15.5% of all AEs being grade 3 or 4 AE. 
None of the individuals with grade 3 or 4 AEs died during or shortly after treatment and only two of 
them stopped treatment early because of AEs. Most of the grade 3 or 4 AEs were caused by elevated 
bilirubin especially when DAAs were concomitantly used with RBV and/or HIV therapy that included 
the protease inhibitor atazanavir, both of which well-known risk factors for elevated bilirubin [28, 29]. 
The low rates of serious laboratory adverse events are in agreement with data from clinical trials [10, 
13, 30] whereas other real-world studies have not reported these events systematically [19-22]. 
 
A major strength of this study is that it provides longitudinal clinical cohort data on a large number of 
individuals across different regions in Europe in a st ndardised way, which allows for comparisons 
between regions and examination of changes over time. In addition, all individual treatments and 
reasons for treatment discontinuation has been centrally reviewed. Our study is also one of the first to 
include data from East and Central East Europe.  However, some of our findings should be interpreted 
with caution. Firstly, we were not able to determine SVR12 for 18% of individuals included in this 
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analysis as we did not have HCV-RNA follow-up data. A proportion of these were known to have end 
of treatment response and it is worth noting that tese are real world data and not all individuals attend 
at set timepoints to assess SVR, nor do all clinics have resources to test.  Not all individuals had dta on 
whether they completed their treatment regimen, however we repeated the analyses among those with 
information on whether they completed treatment, and found the results to be consistent. Also, we may 
have underestimated the number of individuals who stopped due to toxicities, as some centres included 
physician’s decision and patient’s decision as reasons for stopping treatment early, which may have 
overlapped with toxicities. We only systematically collected lab data during treatment for individuals 
that started treatment between 1/6/2014 and 1/10/206 which prevented us from evaluating AEs of 
more recently approved DAA drugs. Also, those with laboratory data and assessed for AEs were 
significantly different from those without lab data and excluded from this analysis. Finally, the 
EuroSIDA cohort may not be representative of HIV/HCV co-infected individuals in general as it 
mainly collects data from university clinics in large European cities.  
In conclusion, our analysis of a large European longitudinal clinical cohort showed similar rates of 
SVR12 to results from other real-life cohorts and oly slightly lower SVR12 rates than in clinical trials. 
This confirms the effectiveness and safety of DAA therapy in HIV/HCV co-infected individuals, and 
supports current treatment recommendations to treatall HCV infected individuals, regardless of co-
infection with HIV.  AC
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Figure 1. Flowchart for inclusion of individuals into analysis 
 
Figure 2: Factors associated with achieving SVR  
 
*Non-ADI: non-AIDS defining malignancy, cardiovascular disease, end-stage liver disease, HCC, end-
stage renal disease, pancreatitis 
†Either a biopsy (METAVIR stage F4), FibroScan (>12.5kPa), APRI (score >2), or hyaluronic acid 
(>250ng/mL) at baseline 
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Table 1: Baseline characteristics at time starting treatment in individuals with known SVR12 status 
    Overall SVR Treatment failure P-
value     n (%) 
 Overall 862 (100.0) 789 (91.5) 73 (8.5) 
Sex Male 672 (78.0) 612 (91.1) 60 (8.9) 
0.361 
Female 190 (22.0) 177 (93.2) 13 (6.8) 
Ethnicity White 770 (89.3) 715 (92.9) 55 (7.1) 
0.0003 Global majority 25 (2.9) 22 (88.0) 3 (12.0) 
Unknown 67 (7.8) 52 (77.6) 15 (22.4) 
Region of 
Europe 
South/Argentina 341 (39.6) 309 (90.6) 32 (9.4) 
0.838 
Central - West 287 (33.3) 264 (92.0) 23 (8.0) 
North 117 (13.6) 107 (91.5) 10 (8.5) 
East/Central - East 117 (13.6) 109 (93.2) 8 (6.8) 
HIV risk group MSM* 204 (23.7) 190 (93.1) 14 (6.9) 
0.141 IDU† 473 (54.9) 425 (89.9) 48 (10.1) 
Other 185 (21.5) 174 (94.1) 11 (5.9) 
HIV-
RNA (cp/ml) 
≤500 818 (94.9) 747 (91.3) 71 (8.7) 
0.423 >500 10 (1.2) 9 (90.0) 1 (10.0) 
Unknown 34 (3.9) 33 (97.1) 1 (2.9) 
Non-ADI† No 699 (81.1) 648 (92.7) 51 (7.3) 
0.010 
Yes 163 (18.9) 141 (86.5) 22 (13.5) 
DAA regimen Sofosbuvir/ledipasvir +/- RBV 423 (49.1) 399 (94.3) 24 (5.7) 
0.002 
Sofosbuvir/daclatasvir +/- RBV 155 (18.0) 140 (90.3) 15 (9.7) 
Ombitasvir/paritaprevir/dasabuvir 
+/- RBV 121 (14.0) 109 (90.1) 12 (9.9) 
Ombitasvir/paritaprevir +/- RBV 39 (4.5) 37 (94.9) 2 (5.1) 
Sofosbuvir/simeprevir +/- RBV 39 (4.5) 29 (74.4) 10 (25.6) 
Other 85 (9.9) 75 (88.2) 10 (11.8) 
Baseline date <2016 477 (55.3) 430 (90.1) 47 (9.9) 
0.104 
≥2016 385 (44.7) 359 (93.2) 26 (6.8) 
Fibrosis‡ F0-F3 618 (71.7) 576 (93.2) 42 (6.8) 
0.012 F4 199 (23.1) 172 (86.4) 27 (13.6) 
Unknown 45 (5.2) 41 (91.1) 4 (8.9) 
HCV genotype G1 496 (57.5) 459 (92.5) 37 (7.5) 
0.564 
G2 14 (1.6) 13 (92.9) 1 (7.1) 
G3 127 (14.7) 116 (91.3) 11 (8.7) 
G4 135 (15.7) 122 (90.4) 13 (9.6) 
Unknown 90 (10.4) 79 (87.8) 11 (12.2) 
Ever received 
cART 
No 30 (3.5) 27 (90.0) 3 (10.0) 
0.735 
Yes 832 (96.5) 762 (91.6) 70 (8.4) 
Prior HCV 
treatment 
No 501 (58.1) 461 (92.0) 40 (8.0) 
0.547 
Yes 361 (41.9) 328 (90.9) 33 (9.1) 
HCV-RNA 
(IU/ml) 
<500000 195 (22.6) 179 (91.8) 16 (8.2) 
0.017 ≥500000 462 (53.6) 432 (93.5) 30 (6.5) 
Positive (unknown value) 205 (23.8) 178 (86.8) 27 (13.2) 
    Median (IQR)  
Age (years) 51 (45-55) 51 (45-55) 52 (46-54) 0.244 
CD4 count  (cells/mm3)  605 (431-813) 612 (433-822) 580 (380-747) 0.092 
CD4 nadir (cells/mm3) 160 (72-265) 160 (70-265) 180 (77-264) 0.525 
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Table 2: Number of laboratory adverse events during treatment by grade 
Biomarker Baseline  During treatment 
Individuals 
with data 
AEs Grade Grade 3 or 4 AE 
Individuals 
with data 
AEs 1 2 3 4 Overall On RBV On 
ATZ* 
Haemoglobin  
(g/dL) 
385 4 (1.0) 451 43 (9.5) 26 (5.8) 10 (2.2) 6 (1.3) 1 (0.3) 7 (1.6) 4 (57.1) 1 (14.3) 
Leukocytes  
(cells/mm3) 
334 4 (1.2) 365 11 (3.0) 8 (2.2) 1 (0.3)  2 (0.5) 2 (0.5) 1 (50.0)  
Neutrophils  
(cells/mm3) 
193 1 (0.5) 227 3 (1.3) 2 (0.9)   1 (0.4) 1 (0.4) 1 (100.0)  
Platelet count  
(cells/mm3) 
403 102 (25.3) 493 141 (28.6) 63 (12.8) 53 (10.8) 24 (4.9) 1 (0.2) 25 (5.1) 11 (44.0) 7 (28.0) 
S-creatinine  
(mg/dL) 
364 26 (7.1) 450 39 (8.7) 19 (4.2) 15 (3.3) 3 (0.7) 2 (0.4) 5 (1.1) 1 (20.0) 1 (20.0) 
ALT† (IU/L) 
 
399 234 (58.6) 488 95 (19.5) 70 (14.3) 18 (3.7) 5 (1.0) 2 (0.4) 7 (1.4) 4 (57.1) 3 (42.9) 
AST‡ (IU/L) 
 
392 189 (48.2) 463 74 (16.0) 62 (13.4) 10 (2.2)  (0.0) 2 (0.4) 2 (0.4) 1 (50.0)  
ALP§ (IU/L) 
 
275 134 (48.7) 315 172 (54.6) 152 (48.3) 17 (5.4) 3 (1.0)  3 (1.0) 1 (33.3)  
Bilirubin 
(mg/dL) 
367 91 (24.8) 439 192 (43.7) 71 (16.2) 54 (12.3) 50 (11.4) 17 (3.9) 67 (15.3) 44 (65.7) 38 (56.7) 
Grades: 1 – mild, 2 – moderate, 3 – severe, 4 – potentially life-threatening  
*ATZ: Atazanavir, †ALT: Alanine aminotransferase, ‡AST: Aspartate aminotransferase, §ALP: Alkaline phosphatase 
When multiple measurements recorded during treatment, the lowest value was included for haemoglobin, leukocytes, neutrophils, platelet count, and highest value was included for s—
creatinine, ALT, AST, ALP and bilirubin 
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Figure 1. Flowchart for inclusion of individuals into analysis 
  
 
 
 
 
 
N=22380
• Individuals in EuroSIDA
N=6770
• Ever HCV-RNA positive
N=1234
• Started IFN-free DAA therapy after June 1st 
2014
N=1042
• Have at least 12 weeks of follow up after end 
of therapy (n=1033) or died with 12 weeks of 
stopping therapy (n=9)
N=862
• Follow up HCV-RNA available to determine 
SVR12
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Figure 2: Factors associated with achieving SVR  
 
*Non-ADI: non-AIDS defining malignancy, cardiovascular disease, end-stage liver disease, HCC, end-stage renal disease, pancreatitis 
†Either a biopsy (METAVIR stage F4), FibroScan (>12.5kPa), APRI (score >2), or hyaluronic acid (>250ng/mL) at baseline 
  
 
Region of Europe
Non-ADI*
Treatment regimen
Baseline date
Fibrosis
HCV-RNA (IU/ml)
South/Argentina
Central - West
North
East/Central - East
No
Yes
Sofosbuvir/ledipasvir 
+/- RBV
Sofosbuvir/daclatasvir 
+/- RBV
Ombitasvir/paritaprevi
r/dasabuvir +/- RBV
Ombitasvir/paritaprevi
r +/- RBV
Sofosbuvir/simeprevir 
+/- RBV
Other
per 6 months later
≤F3
F4†
<500000
≥500000 
Positive (unknown 
value)
1.00
0.94 (0.51-1.72)
0.76 (0.34-1.69)
1.32 (0.54-3.25)
1.00
0.53 (0.30-0.95)
1.00
0.71 (0.35-1.45)
0.46 (0.22-1.00)
0.92 (0.20-4.15)
0.21 (0.08-0.53)
0.50 (0.22-1.11)
1.04 (0.85-1.27)
1.00
0.61 (0.34-1.09)
1.00
1.26 (0.66-2.40)
0.50 (0.25-0.99)
0.00 0.01 0.10 1.00 10.00 100.00
Adjusted odds ratio (95% CI)
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